Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback